Related Experiment Video
Updated: Jul 1, 2025
08:43
Advanced Cardiac Rhythm Management by Applying Optogenetic Multi-Site Photostimulation in Murine Hearts
Published on: August 26, 2021
2.4K
Non-invasive Neuromodulation of Arrhythmias
Johnathon Rast1, Daniel Sohinki1, Alexander Warner1
1Medical College of Georgia, Augusta, GA, USA.
The Journal of Innovations in Cardiac Rhythm Management
|March 6, 2024
Summary
Non-invasive strategies modulating the cardiac autonomic nervous system (CANS) show promise for treating atrial fibrillation and ventricular arrhythmias. These low-risk approaches offer potential adjuvant therapies for managing complex cardiac conditions.
Area of Science:
- Cardiology
- Neuroscience
- Medical Technology
Background:
- Cardiac autonomic nervous system (CANS) dysfunction is linked to various cardiac arrhythmias.
- Invasive CANS modulation, like sympathetic denervation, is established for treating arrhythmias such as ventricular tachycardia storm.
- Non-invasive strategies are emerging as a low-risk, adjuvant therapeutic approach.
Purpose of the Study:
- To review current non-invasive technologies for modulating the CANS.
- To assess the evidence for using these technologies in suppressing atrial fibrillation and ventricular arrhythmias.
- To provide an evidence-based overview for future research and clinical application.
Main Methods:
- Literature review of current non-invasive CANS modulation technologies.
- Analysis of studies investigating the efficacy of these technologies for arrhythmia suppression.
- Evidence-based assessment of technological approaches for atrial fibrillation and ventricular arrhythmias.
Main Results:
- Non-invasive CANS modulation technologies are under investigation for arrhythmia management.
- These methods offer a potentially safer alternative or adjunct to invasive procedures.
- Evidence supports the exploration of these techniques for atrial fibrillation and ventricular arrhythmias.
Conclusions:
- Non-invasive modulation of the CANS represents a promising frontier in arrhythmia treatment.
- Further research is needed to fully establish the efficacy and safety of these technologies.
- These approaches may broaden therapeutic options for patients with atrial fibrillation and ventricular arrhythmias.
Related Concept Videos
01:28Mechanism of Cardiac Arrhythmias
919
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
919
01:28Disturbances in Heart Rhythm
952
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
952
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
743
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
743
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
994
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
994
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
832
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
832